Combination Gene Therapy and Th1Th2 Therapy

我们的工作重点是利用慢病毒载体将基因转移到雷帕霉素耐药的T细胞。使用这种方法，可以诱导特定培养中的大多数T细胞表达新基因。我们还开发了动物模型来测试这些免疫基因治疗策略的体内效应。这些模型包括肿瘤并评估移植物抗宿主病，移植物抗宿主病仍然是异基因造血干细胞移植后的主要并发症。为了促进这一项目的实施，我们与Lentigen公司签订了一项合作研究协议，以开发专注于慢病毒传递自杀基因的临床方案。相关肿瘤部位：非霍奇金淋巴瘤、白血病。相关研究领域：基因治疗、骨髓移植、器官移植研究、综合治疗方案、血液学/淋巴学。

We have focused our efforts on the use of lentiviral vectors to transfer genes to the rapamycin-resistant T cells. Using this approach, the majority of T cells in a given culture can be induced to express the new gene. We have also developed animal models to test the in vivo effect of these immuno-gene therapy strategies. Such models incorporate tumors and also evaluate graft-versus-host disease, which remains the main complication after allogeneic hematopoietic stem cell transplantation. To facilitate implementation of this project, we have entered into a cooperative research agreement with Lentigen Corporation to develop clinical protocols focusing on lentiviral delivery of suicide genes. Relevant cancer sites: Non-Hodgkins Lymphoma, Leukemia. Relevant Research Areas: Gene Therapy, Bone Marrow Transplantation, Organ Transplantation Research, Combined Treatment Modalities, Hematology/Lymph.